no Amevive for HIV+ people
Stock Market News and Investment Information | Reuters.com
WASHINGTON, Nov 10 (Reuters) - Biogen Idec's (BIIB.O: Quote, Profile, Research) skin drug Amevive should not be used in patients who have HIV because it may speed up progression of the virus or cause more complications, the biotechnology company and U.S. health regulators said on Thursday.
Amevive, which is approved to treat moderate to severe chronic plaque psoriasis, can reduce the amount of certain white blood cells, Biogen and the Food and Drug Administration said on the agency's Web site
WASHINGTON, Nov 10 (Reuters) - Biogen Idec's (BIIB.O: Quote, Profile, Research) skin drug Amevive should not be used in patients who have HIV because it may speed up progression of the virus or cause more complications, the biotechnology company and U.S. health regulators said on Thursday.
Amevive, which is approved to treat moderate to severe chronic plaque psoriasis, can reduce the amount of certain white blood cells, Biogen and the Food and Drug Administration said on the agency's Web site
posted by Dr Philippe Maslo at 19:34
0 Comments:
Post a Comment
<< Home